Figure 8

Electrophoretic mobility shift analysis (EMSA) of NF-κB binding sites derived from the human COX-2 promoter. Nuclear extracts derived form HeLa cells without treatment (-, lanes 1, 4, 7), with TNFα treatment (lanes 2, 5, 8) and with PMA treatment (lanes 3, 6, 9) were used for EMSA with different probes. EMSA with a probe spanning the promoter element NF-κB₁ from the human COX-2 promoter is shown in lane 1–3. NF-κB₂ was used as probe in lane 4–6 and a κB-element from the κ light chain enhancer was used as control in lanes 7–9. The specific NF-κB complex is marked with an arrowhead.